Dr. Reddys Lab receives EIR from USFDA for Formulations Plant 3 in Hyderabad

16 Apr 2019 Evaluate

Dr. Reddys Laboratories has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA), for the company’s Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad.

Earlier, in February, 2019 this site had undergone an audit by the USFDA, wherein the company was issued a Form 483 with 11 observations. Based on the responses and follow up actions, the US FDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1218.40 9.95 (0.82%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×